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tial dosimetric information. It allows an accurate, systematic numerical 
and patient-speciﬁc study of the relationship between RT-induced ﬁbro-
sis and local dose. Very good correlations were obtained between local 
MC doses and the probability of RT-induced ﬁbrosis. The methodology 
presented in this paper may have important implications in future dose 
escalation studies. 
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Background: Stereotactic radiotherapy (SRT) using 4-dimensional 
(4D) target deﬁnition for NSCLC has been performed at the VU Uni-
versity Medical Center since April 2003. Patients with Stage I NSCLC 
who were medically unﬁt for surgery or refused such treatment were 
eligible for SRT. Patients were closely followed-up using a standard 
schedule of up to four follow-up CT scans in the two years following 
SRT. Outcomes in the ﬁrst 197 patients with 210 primary lung tumors 
were analyzed.
Methods: The group consisted of 164 medically inoperable patients 
and 33 who refused surgery. The median age was 73 years, and 154 
T1 tumors (73%) and 56 T2 tumors (27%) were treated. Pre-treatment 
histological conﬁrmation of malignancy was obtained in 61 patients 
(31%). The other patients had new and/or growing, PET-positive le-
sions (a previous randomised study in our region had revealed that the 
incidence of benign lesions in such a situation was less than 5%). In-
dividualized internal target volumes (ITV) were generated by contour-
ing maximum-intensity projections from 4DCT scans. Planning target 
volumes (PTV) were derived by adding a 3 mm margin to the ITV to 
account for residual patient setup errors using the Novalis Exactrac on-
line setup procedure. SRT was delivered using 8-12 non-coplanar static 
beams. Fractionation schemes were 3x20 Gy (n=86) for T1 tumors, 
5x12 Gy (n=97) for either T1 tumors adjacent to the thoracic wall/me-
diastinum or T2 tumors, and 8x7.5 Gy (n=27) for lesions adjacent to 
the pericardium or hilus, all prescribed at the 80% isodose. 
Results: Median overall survival was 34 months, with actuarial overall 
survival of 79% and 63% at 1 and 2 years, respectively. Follow-up 
imaging showed local failures in 6 patients (no histological conﬁrma-
tion), resulting in an actuarial local failure-free survival rate of 94% 
at two years. Despite a pre-treatment FDG-PET in all but 3 patients, 
regional failure was observed in 16 patients at a median interval of 7 
months. The actuarial regional failure-free survival at 1 and 2 years 
was 94% and 85%. Regional recurrences were located in the ipsilateral 
hilus (n=4), the mediastinum (n=6), or both (n=6). Distant failure free 
survival rates at 1 and 2 years were 86% and 79%, respectively. Overall 
and disease-free survival was not signiﬁcantly different in patients with 
or without histological conﬁrmation of malignancy (Figure 1). Out-
comes in stage IB disease were worse than in stage IA for both overall 
(p=0.02) and disease-free survival (p=0.04) (Figure 2). 
Early toxicity was mild, with fatigue (32%), nausea (10%), and chest 
pain (8%) being the most frequently reported. Late toxicity was un-
common, with grade ≥3 radiation pneumonitis in 6 patients (3%). Rib 
fractures and chronic chest wall pain syndromes were observed in 3 
patients each. 
Conclusions: Local control rates of ≥90% are achieved using SRT, 
making it an effective alternative to surgery in patients who are margin-
ally ﬁt for operation or refusing surgery. The incidence of severe early 
or late toxicity is low. As was also reported following surgery, regional 
and/or distant failure is the most common pattern of relapse in stage I 
NSCLC despite pre-treatment FDG-PET scans.
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Background: Stereotactic-body-radiotherapy (SBRT) is a treatment 
regime for Stage I lung cancer patients showing very high local control 
rates. To limit toxicity, treatment volumes need to be minimized requir-
ing high precision treatment techniques. We propose the use of four 
dimensional (4D) cone beam CT (CBCT) guidance to minimize treat-
ment delivery errors.
